This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (306)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Breast Cancer  • Alert me on articles by topic  Social Bookmarking   What's this?

Lisa A. Carey, MD; Charles M. Perou, PhD; Chad A. Livasy, MD; Lynn G. Dressler, PhD; David Cowan, BS; Kathleen Conway, PhD; Gamze Karaca, MSc; Melissa A. Troester, PhD; Chiu Kit Tse, MSPH; Sharon Edmiston, BS; Sandra L. Deming, PhD, MPH; Joseph Geradts, MD; Maggie C. U. Cheang, MMedSci; Torsten O. Nielsen, MD; Patricia G. Moorman, PhD; H. Shelton Earp, MD; Robert C. Millikan, DVM, PhD

JAMA. 2006;295:2492-2502.

Context  Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (HER2+/ER–), luminal A, and luminal B.

Objectives  To determine population-based distributions and clinical associations for breast cancer subtypes.

Design, Setting, and Participants  Immunohistochemical surrogates for each subtype were applied to 496 incident cases of invasive breast cancer from the Carolina Breast Cancer Study (ascertained between May 1993 and December 1996), a population-based, case-control study that oversampled premenopausal and African American women. Subtype definitions were as follows: luminal A (ER+ and/or progesterone receptor positive [PR+], HER2–), luminal B (ER+ and/or PR+, HER2+), basal-like (ER–, PR–, HER2–, cytokeratin 5/6 positive, and/or HER1+), HER2+/ER– (ER–, PR–, and HER2+), and unclassified (negative for all 5 markers).

Main Outcome Measures  We examined the prevalence of breast cancer subtypes within racial and menopausal subsets and determined their associations with tumor size, axillary nodal status, mitotic index, nuclear pleomorphism, combined grade, p53 mutation status, and breast cancer–specific survival.

Results  The basal-like breast cancer subtype was more prevalent among premenopausal African American women (39%) compared with postmenopausal African American women (14%) and non–African American women (16%) of any age (P<.001), whereas the luminal A subtype was less prevalent (36% vs 59% and 54%, respectively). The HER2+/ER– subtype did not vary with race or menopausal status (6%-9%). Compared with luminal A, basal-like tumors had more TP53 mutations (44% vs 15%, P<.001), higher mitotic index (odds ratio [OR], 11.0; 95% confidence interval [CI], 5.6-21.7), more marked nuclear pleomorphism (OR, 9.7; 95% CI, 5.3-18.0), and higher combined grade (OR, 8.3; 95% CI, 4.4-15.6). Breast cancer–specific survival differed by subtype (P<.001), with shortest survival among HER2+/ER– and basal-like subtypes.

Conclusions  Basal-like breast tumors occurred at a higher prevalence among premenopausal African American patients compared with postmenopausal African American and non–African American patients in this population-based study. A higher prevalence of basal-like breast tumors and a lower prevalence of luminal A tumors could contribute to the poor prognosis of young African American women with breast cancer.

Author Affiliations: Division of Hematology/Oncology (Dr Carey), Departments of Medicine (Drs Dressler and Earp and Mr Cowan), Genetics (Dr Perou and Ms Karaca), and Pathology (Drs Perou and Livasy), School of Public Health, Department of Epidemiology (Drs Conway, Troester, Deming, and Millikan and Mss Tse and Edmiston), University of North Carolina-Lineberger Comprehensive Cancer Center, Chapel Hill; Department of Community and Family Medicine, Duke University Medical Center, Durham, NC (Dr Moorman); Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver (Dr Nielsen and Ms Cheang); and Roswell Park Cancer Institute, Buffalo, NY (Dr Geradts).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Triple-negative breast cancer--current status and future directions
Gluz et al.
Ann Oncol 2009;0:mdp492v1-mdp492.
ABSTRACT | FULL TEXT  

Breast Cancer Recurrence in Older Women Five to Ten Years after Diagnosis
Bosco et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:2979-2983.
ABSTRACT | FULL TEXT  

An Admixture Scan in 1,484 African American Women with Breast Cancer
Fejerman et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:3110-3117.
ABSTRACT | FULL TEXT  

High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy
Trere et al.
Ann Oncol 2009;20:1818-1823.
ABSTRACT | FULL TEXT  

Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor-Negative Breast Cancer
Speers et al.
Clin. Cancer Res. 2009;15:6327-6340.
ABSTRACT | FULL TEXT  

Prediction of Local Recurrence, Distant Metastases, and Death After Breast-Conserving Therapy in Early-Stage Invasive Breast Cancer Using a Five-Biomarker Panel
Millar et al.
JCO 2009;27:4701-4708.
ABSTRACT | FULL TEXT  

The role of VEGF in triple-negative breast cancer: where do we go from here?
Dent
Ann Oncol 2009;20:1615-1617.
FULL TEXT  

Bioinformatics and breast cancer: what can high-throughput genomic approaches actually tell us?
Sims
J. Clin. Pathol. 2009;62:879-885.
ABSTRACT | FULL TEXT  

Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer
Huo et al.
JCO 2009;27:4515-4521.
ABSTRACT | FULL TEXT  

Dietary patterns and breast cancer risk in women participating in the Black Women's Health Study
Agurs-Collins et al.
Am. J. Clin. Nutr. 2009;90:621-628.
ABSTRACT | FULL TEXT  

Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial
Sanoff et al.
JCO 2009;27:4109-4115.
ABSTRACT | FULL TEXT  

A Loss-of-Function Polymorphism in the Propeptide Domain of the LOX Gene and Breast Cancer
Min et al.
Cancer Res. 2009;69:6685-6693.
ABSTRACT | FULL TEXT  

Second Primary Breast Cancer Occurrence According to Hormone Receptor Status
Kurian et al.
JNCI J Natl Cancer Inst 2009;101:1058-1065.
ABSTRACT | FULL TEXT  

African American Women Who Receive Primary Anthracycline- and Taxane-Based Chemotherapy for Triple-Negative Breast Cancer Suffer Worse Outcomes Compared With White Women
Balmanoukian et al.
JCO 2009;27:e35-e37.
FULL TEXT  

Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients of the Southwest Oncology Group
Albain et al.
JNCI J Natl Cancer Inst 2009;101:984-992.
ABSTRACT | FULL TEXT  

Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1
Pintens et al.
J. Clin. Pathol. 2009;62:624-628.
ABSTRACT | FULL TEXT  

Time-Varying Effects of Prognostic Factors Associated With Disease-Free Survival in Breast Cancer
Natarajan et al.
Am J Epidemiol 2009;169:1463-1470.
ABSTRACT | FULL TEXT  

A Mitochondrial Target Sequence Polymorphism in Manganese Superoxide Dismutase Predicts Inferior Survival in Breast Cancer Patients Treated with Cyclophosphamide
Glynn et al.
Clin. Cancer Res. 2009;15:4165-4173.
ABSTRACT | FULL TEXT  

Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
Smith et al.
JCO 2009;27:2758-2765.
ABSTRACT | FULL TEXT  

Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia
Lin et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:1807-1814.
ABSTRACT | FULL TEXT  

Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival
Onitilo et al.
Clin Med Res 2009;7:4-13.
ABSTRACT | FULL TEXT  

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Cheang et al.
JNCI J Natl Cancer Inst 2009;101:736-750.
ABSTRACT | FULL TEXT  

Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status: The Multiethnic Cohort Study
Setiawan et al.
Am J Epidemiol 2009;169:1251-1259.
ABSTRACT | FULL TEXT  

Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Studies S8814/S8897
Hershman et al.
JCO 2009;27:2157-2162.
ABSTRACT | FULL TEXT  

The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype
Heikkinen et al.
Clin. Cancer Res. 2009;15:3214-3222.
ABSTRACT | FULL TEXT  

Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland
Spitale et al.
Ann Oncol 2009;20:628-635.
ABSTRACT | FULL TEXT  

Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development
Fasano and Muggia
Ann Oncol 2009;20:609-614.
ABSTRACT | FULL TEXT  

Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Rakha et al.
Clin. Cancer Res. 2009;15:2302-2310.
ABSTRACT | FULL TEXT  

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
Hugh et al.
JCO 2009;27:1168-1176.
ABSTRACT | FULL TEXT  

Is There a Difference in the Association between Percent Mammographic Density and Subtypes of Breast Cancer? Luminal A and Triple-Negative Breast Cancer
Ma et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:479-485.
ABSTRACT | FULL TEXT  

High Frequency of TP53 Mutation in BRCA1 and Sporadic Basal-like Carcinomas but not in BRCA1 Luminal Breast Tumors
Manie et al.
Cancer Res. 2009;69:663-671.
ABSTRACT | FULL TEXT  

Triple Receptor-Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes
Dawood et al.
JCO 2009;27:220-226.
ABSTRACT | FULL TEXT  

Microarrays and Epidemiology: Ensuring the Impact and Accessibility of Research Findings
Troester et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:1-4.
FULL TEXT  

Trends in Area-Socioeconomic and Race-Ethnic Disparities in Breast Cancer Incidence, Stage at Diagnosis, Screening, Mortality, and Survival among Women Ages 50 Years and Over (1987-2005)
Harper et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:121-131.
ABSTRACT | FULL TEXT  

Eliminating Global Disparities in Breast Cancer Care through Clinical Research
Olofin and Olopade
Am Soc Clin Oncol Ed Book 2009;2009:681-684.
ABSTRACT | FULL TEXT  

Age-Related Crossover in Breast Cancer Incidence Rates Between Black and White Ethnic Groups
Anderson et al.
JNCI J Natl Cancer Inst 2008;100:1804-1814.
ABSTRACT | FULL TEXT  

Advances in Breast Cancer: Pathways to Personalized Medicine
Olopade et al.
Clin. Cancer Res. 2008;14:7988-7999.
ABSTRACT | FULL TEXT  

Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider et al.
Clin. Cancer Res. 2008;14:8010-8018.
ABSTRACT | FULL TEXT  

Reducing Disparities in Breast Cancer Care--A Daunting but Essential Responsibility
Freedman and Winer
JNCI J Natl Cancer Inst 2008;100:1661-1663.
FULL TEXT  

Triple-Negative Breast Cancer and Obesity in a Rural Appalachian Population
Vona-Davis et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:3319-3324.
ABSTRACT | FULL TEXT  

Do Placental Genes Affect Maternal Breast Cancer? Association between Offspring's CGB5 and CSH1 Gene Variants and Maternal Breast Cancer Risk
Chen et al.
Cancer Res. 2008;68:9729-9734.
ABSTRACT | FULL TEXT  

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
Di Leo et al.
JCO 2008;26:5544-5552.
ABSTRACT | FULL TEXT  

Skewed X Chromosome Inactivation and Breast and Ovarian Cancer Status: Evidence for X-Linked Modifiers of BRCA1
Lose et al.
JNCI J Natl Cancer Inst 2008;100:1519-1529.
ABSTRACT | FULL TEXT  

Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast Cancer
Dawood et al.
JCO 2008;26:4891-4898.
ABSTRACT | FULL TEXT  

Caffeine Consumption and the Risk of Breast Cancer in a Large Prospective Cohort of Women
Ishitani et al.
Arch Intern Med 2008;168:2022-2031.
ABSTRACT | FULL TEXT  

Differences in Estrogen Receptor Subtype According to Family History of Breast Cancer among Hispanic, but not Non-Hispanic White Women
Hines et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:2700-2706.
ABSTRACT | FULL TEXT  

Breast Cancer Survival among Economically Disadvantaged Women: The Influences of Delayed Diagnosis and Treatment on Mortality
Smith et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:2882-2890.
ABSTRACT | FULL TEXT  

Body Size and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer in Postmenopausal Women
Phipps et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:2078-2086.
ABSTRACT | FULL TEXT  

Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)
Mrozek et al.
Ann Oncol 2008;19:1417-1422.
ABSTRACT | FULL TEXT  

Targeting Src in breast cancer
Finn
Ann Oncol 2008;19:1379-1386.
ABSTRACT | FULL TEXT  

An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes
Melchor and Benitez
Carcinogenesis 2008;29:1475-1482.
ABSTRACT | FULL TEXT  

Breast Cancer in Young Women: A New Color or a Different Shade of Pink?
Peppercorn and Partridge
JCO 2008;26:3303-3305.
FULL TEXT  

Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
Anders et al.
JCO 2008;26:3324-3330.
ABSTRACT | FULL TEXT  

Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening
Sihto et al.
Clin. Cancer Res. 2008;14:4103-4110.
ABSTRACT | FULL TEXT  

Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B
Polite et al.
JCO 2008;26:2659-2665.
ABSTRACT | FULL TEXT  

Basal-Like Breast Cancer: A Critical Review
Rakha et al.
JCO 2008;26:2568-2581.
ABSTRACT | FULL TEXT  

A Prospective Study of Multivitamin Supplement Use and Risk of Breast Cancer
Ishitani et al.
Am J Epidemiol 2008;167:1197-1206.
ABSTRACT | FULL TEXT  

Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy
Nguyen et al.
JCO 2008;26:2373-2378.
ABSTRACT | FULL TEXT  

Basal carcinoma of the breast revisited: an old entity with new interpretations
Korsching et al.
J. Clin. Pathol. 2008;61:553-560.
ABSTRACT | FULL TEXT  

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy
Gilbert et al.
Molecular Cancer Therapeutics 2008;7:944-951.
ABSTRACT | FULL TEXT  

Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group
Kyndi et al.
JCO 2008;26:1419-1426.
ABSTRACT | FULL TEXT  

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
Liedtke et al.
JCO 2008;26:1275-1281.
ABSTRACT | FULL TEXT  

A Human Breast Cell Model of Preinvasive to Invasive Transition
Rizki et al.
Cancer Res. 2008;68:1378-1387.
ABSTRACT | FULL TEXT  

Targeting Health Disparities: A Model Linking Upstream Determinants To Downstream Interventions
Gehlert et al.
Health Aff (Millwood) 2008;27:339-349.
ABSTRACT | FULL TEXT  

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
Cheang et al.
Clin. Cancer Res. 2008;14:1368-1376.
ABSTRACT | FULL TEXT  

Analysis of Integrin {beta}4 Expression in Human Breast Cancer: Association with Basal-like Tumors and Prognostic Significance
Lu et al.
Clin. Cancer Res. 2008;14:1050-1058.
ABSTRACT | FULL TEXT  

Estrogen Receptor-Negative Invasive Breast Cancer: Imaging Features of Tumors with and without Human Epidermal Growth Factor Receptor Type 2 Overexpression
Wang et al.
Radiology 2008;246:367-375.
ABSTRACT | FULL TEXT  

Increased Uptake of BRCA1/2 Genetic Testing Among African American Women With a Recent Diagnosis of Breast Cancer
Susswein et al.
JCO 2008;26:32-36.
ABSTRACT | FULL TEXT  

Evolving Strategies for the Treatment of "Triple-Negative" Breast Cancer
Wasserman and Tan
Am Soc Clin Oncol Ed Book 2008;2008:120-126.
ABSTRACT | FULL TEXT  

Integrated Profiling of Basal and Luminal Breast Cancers
Adelaide et al.
Cancer Res. 2007;67:11565-11575.
ABSTRACT | FULL TEXT  

Altered MicroRNA Expression Confined to Specific Epithelial Cell Subpopulations in Breast Cancer
Sempere et al.
Cancer Res. 2007;67:11612-11620.
ABSTRACT | FULL TEXT  

Magnetic Resonance Imaging in Predicting Pathological Response of Triple Negative Breast Cancer Following Neoadjuvant Chemotherapy
Chen et al.
JCO 2007;25:5667-5669.
FULL TEXT  

Epithelial to Mesenchymal Transition in Human Breast Epithelial Cells Transformed by 17 -Estradiol
Huang et al.
Cancer Res. 2007;67:11147-11157.
ABSTRACT | FULL TEXT  

Triple-negative breast cancer: MRI features in 29 patients
Chen et al.
Ann Oncol 2007;18:2042-2043.
FULL TEXT  

Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience
Aksoy et al.
Ann Oncol 2007;18:1904-1906.
FULL TEXT  

Factors Associated with Advanced Disease Stage at Diagnosis in a Population-based Study of Patients with Newly Diagnosed Breast Cancer
Hahn et al.
Am J Epidemiol 2007;166:1035-1044.
ABSTRACT | FULL TEXT  

Hormonal Markers in Breast Cancer: Coexpression, Relationship with Pathologic Characteristics, and Risk Factor Associations in a Population-Based Study
Yang et al.
Cancer Res. 2007;67:10608-10617.
ABSTRACT | FULL TEXT  

Women's Interest in Gene Expression Analysis for Breast Cancer Recurrence Risk
O'Neill et al.
JCO 2007;25:4628-4634.
ABSTRACT | FULL TEXT  

Interventions to Enhance Breast Cancer Screening, Diagnosis, and Treatment among Racial and Ethnic Minority Women
Masi et al.
Med Care Res Rev 2007;64:195S-242S.
ABSTRACT  

FOXA1 Expression in Breast Cancer Correlation with Luminal Subtype A and Survival
Badve et al.
Clin. Cancer Res. 2007;13:4415-4421.
ABSTRACT | FULL TEXT  

Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
Dent et al.
Clin. Cancer Res. 2007;13:4429-4434.
ABSTRACT | FULL TEXT  

The E2F-Regulated Gene Chk1 Is Highly Expressed in Triple-Negative Estrogen Receptor /Progesterone Receptor /HER-2 Breast Carcinomas
Verlinden et al.
Cancer Res. 2007;67:6574-6581.
ABSTRACT | FULL TEXT